Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.'s Brovana®

Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).

Cipla's Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.'s Brovana®.

Brovana® is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for:

- Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

According to IQVIA (IMS Health), Brovana® had US sales of approximately $438M for the 12-month period ending April 2021.

The product is available for shipping immediately.

Shares of CIPLA LTD. was last trading in BSE at Rs.957.8 as compared to the previous close of Rs. 955.65. The total number of shares traded during the day was 644460 in over 2443 trades.

The stock hit an intraday high of Rs. 965.8 and intraday low of 954.5. The net turnover during the day was Rs. 616222454.

Source : Equity Bulls

Keywords